Human Trials to Begin on Hepatitis C Drug | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Immune Activation Repurposed for Developing Hepatitis C Therapy

Back to News Homepage
Next

Hepatitis Awareness: 10 Liver Cancer Risks

Human Trials to Begin on Hepatitis C Drug

The Editors at Hepatitis Central
February 21, 2011

Print this page

After encouraging pre-clinical studies, Medivir and Tibotec are beginning a Phase 1a trial of their Hepatitis C nucleoside inhibitor.

Medivir Kicks Off Phase 1a Trial of the Hepatitis C Polymerase Inhibitor TMC649128

Feb 16, 2011 (Close-Up Media via COMTEX) —

Medivir AB, a research-based specialty pharmaceutical company focused on infectious diseases, announced the start of a phase 1a clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus infection.

The Company said TMC649128 is a nucleoside NS5B polymerase inhibitor that has already demonstrated an attractive pre-clinical profile. It is anticipated that this profile would see TMC649128 be used in combination with HCV directly acting antiviral agents, given their high genetic barrier to resistance and antiviral activity across multiple HCV genotypes.

Continue reading this entire article:
http://www.tradingmarkets.com/news/stock-alert/mvrbf_medivir-kicks-off-phase-1a-trial-of-the-hepatitis-c-polymerase-inhibitor-tmc649128-1494826.html

No Comments - be the first!
Share
Share
Previous

Immune Activation Repurposed for Developing Hepatitis C Therapy

Back to News Homepage
Next

Hepatitis Awareness: 10 Liver Cancer Risks

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.